Cargando…

Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

BACKGROUND: Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiuting, Cheng, Wei, Fan, Shengxian, Huang, Yuhua, Chen, Xi, Jiang, Zhiwei, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207711/
https://www.ncbi.nlm.nih.gov/pubmed/34134659
http://dx.doi.org/10.1186/s12879-021-06270-w
_version_ 1783708825321209856
author Hu, Xiuting
Cheng, Wei
Fan, Shengxian
Huang, Yuhua
Chen, Xi
Jiang, Zhiwei
Wang, Jian
author_facet Hu, Xiuting
Cheng, Wei
Fan, Shengxian
Huang, Yuhua
Chen, Xi
Jiang, Zhiwei
Wang, Jian
author_sort Hu, Xiuting
collection PubMed
description BACKGROUND: Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. METHODS: 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. RESULTS: The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. CONCLUSION: Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06270-w.
format Online
Article
Text
id pubmed-8207711
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82077112021-06-16 Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis Hu, Xiuting Cheng, Wei Fan, Shengxian Huang, Yuhua Chen, Xi Jiang, Zhiwei Wang, Jian BMC Infect Dis Research BACKGROUND: Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. METHODS: 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. RESULTS: The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. CONCLUSION: Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06270-w. BioMed Central 2021-06-16 /pmc/articles/PMC8207711/ /pubmed/34134659 http://dx.doi.org/10.1186/s12879-021-06270-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hu, Xiuting
Cheng, Wei
Fan, Shengxian
Huang, Yuhua
Chen, Xi
Jiang, Zhiwei
Wang, Jian
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_full Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_fullStr Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_full_unstemmed Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_short Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_sort therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207711/
https://www.ncbi.nlm.nih.gov/pubmed/34134659
http://dx.doi.org/10.1186/s12879-021-06270-w
work_keys_str_mv AT huxiuting therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT chengwei therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT fanshengxian therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT huangyuhua therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT chenxi therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT jiangzhiwei therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT wangjian therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis